Gastrointestinal Stromal Tumor – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of GIST for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

Clarivate Epidemiology’s GIST forecast will answer the following questions:

  • Of all people diagnosed with GIST, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GIST over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 24 GIST patient populations, including the following:

  • Diagnosed GIST incident cases.
  • Diagnosed non-metastatic resectable GIST incident cases.
  • Diagnosed non-metastatic unresectable GIST incident cases.
  • Diagnosed nonmetastatic resectable GIST incident cases by NIH criteria.
  • Diagnosed nonmetastatic resectable GIST incident cases by modified NIH criteria.
  • Diagnosed metastatic GIST incident cases.
  • Diagnosed metastatic recurrent incident cases from resectable GIST.
  • Diagnosed GIST prevalent cases.
  • Diagnosed GIST first line metastatic drug treatable population.
  • … and many more (details available on request).

Note: Coverage may vary by country.

Table of contents

  • Gastrointestinal Stromal Tumor - Epidemiology - Mature Markets
    • Epidemiology data
    • Methods
      • Literature review (studies included in/excluded from the analyses of GIST)
      • Diagnosed incident cases of GIST
      • Stage distribution of GIST
      • GIST by location
      • Risk stratification
      • Incident cases of recurrent GIST
      • Diagnosed prevalent cases of GIST
      • Drug-treatable populations
      • Risk / protective factors applied to disease forecast models
    • Reference materials
      • Bibliography
      • Glossary
      • Abbreviation table